Not one of my better days
- This topic has 7 replies, 7 voices, and was last updated 9 years, 6 months ago by
.
-
Posts
-
Thanks guys. I took a couple on the chin yeserday but I’m back up on my feet now. Time to re-read what I’ve advised others and put my name at the beginning as well as the end.
Will let you know which path Aimee and I go down.
Duke
I am very sorry to hear about this. My husband used irinotican and it did not work for him either. Have you been treated with erlotinib and avastin? Both drugs are targeted agents and approved for other indications. clinical trial data (UpToDate Oncology) showed promising results in patients with cholangiocarcinoma. This is the BEST regimen my husband has ever responded and very well tolerated.. You may want to talk to your onc and ask for off-label use. Below is published data in UpToDate Oncology. Best of luck!!
Lee
Erlotinib plus bevacizumab — Vascular endothelial growth factor (VEGF) is overexpressed in biliary tract cancers and has been proposed as a therapeutic target [57]. The efficacy of bevacizumab, a monoclonal antibody targeting VEGF, in combination with erlotinib was addressed in a multinational phase II study [58]. Fifty-three patients with advanced cholangiocarcinoma (n = 43) or gallbladder cancer (n = 10) received bevacizumab (5 mg/kg every two weeks) plus erlotinib (150 mg once daily). Nine patients achieved a PR, which was sustained beyond four weeks in six (12 percent), with a median response duration of 8.4 months. Stable disease was documented in 51 percent. In the entire group, the median time to disease progression was 4.4 months, and median overall survival 9.9 months. Four patients (8 percent) developed grade 4 toxicity (cerebral ischemia or thrombosis), and the most frequent grade 3 toxicity was skin rash (three patients), although in all, 40 patients developed a rash of any grade during therapy.
Duke,
Real sorry to hear this latest news from you. Not what you or anyone wanted to hear. So hoping that you get onto the AG-120 trial and am keeping everything possible crossed for you with this one. You know you’ve got all of us here wishing you every success with this and loads of positive thoughts are heading over the pond to you.
Thinking of you,
Gavin
Duke,
So sorry to read your post. I ‘m glad you have another trail you are trying to get in to. I hope you hear soon and they let you in. You’re in my prayers.
Sherri
Duke,
Sorry to read this. 83k vs 100k is only 20%. I understand on there being limits, but wonder if clinically there is much of a difference in the two levels.
Fingers are crossed for getting into the trial.
Take care,
CatherineAw, Cuz, so sorry to hear this but you never know what the next one will do and hopefully it will hold the winning ticket!! Keeping you in my thoughts, always. Sure do miss you!
CT scan last Friday showed that irinotecan was no longer working. No evidence it ever did. Irinotecan before that showed little effect – maintaining stable is the best that might be said of it.
Trying to get into AG-120 trial (NCT02073994). If that falls through, docetaxel appears to be the last apple in the basket. Main problem with trials is that my platelets have steadied about at about 83,000. Most require above 100,000.
Duke
- The forum ‘General Discussion’ is closed to new topics and replies.